Intravitreal administration of dexamethasone-loaded PLGA-TPGS nanoparticles for the treatment of posterior segment diseases

Journal of Biomedical Nanotechnology

Volumn 9, Issue 9, 2013, Pages 1617-1623

  Yang, Chenming ^a   Jiang, Liqin ^b   Bu, Sijiang ^a   Zhang, Lihua ^a   Xie, Xiaojun ^a   Zeng, Qingguo ^a   Zhu, Dunwan ^b   Zheng, Yi ^c  

^a Xili University Town   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

^c TSINGHUA UNIVERSITY   (China)

Author keywords

Dexamethasone; Intravitreal injection; Nanoparticles; Pharmacokinetics; PLGA TPGS

Indexed keywords

DEXAMETHASONES; ENTRAPMENT EFFICIENCY; EXPERIMENTAL GROUPS; INTRAVITREAL INJECTION; MEAN CONCENTRATIONS; NANOPARTICLE SUSPENSION; PLGA-TPGS; SIZE AND SIZE DISTRIBUTIONS;

BIOCHEMISTRY; COPOLYMERS; DRUG PRODUCTS; DRUG THERAPY; NANOPARTICLES; PHARMACOKINETICS; SUSPENSIONS (FLUIDS);

DISEASES;

DEXAMETHASONE; DEXTRO ALPHA TOCOPHERYL POLYETHYLENE GLYCOL 1000 SUCCINATE; MACROGOL; NANOPARTICLE; POLYLACTIDE; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AQUEOUS HUMOR; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORNEA; DRUG BIOAVAILABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IRIS; LENS; MORPHOLOGY; NANOFABRICATION; NONHUMAN; PARTICLE SIZE; POSTERIOR EYE SEGMENT; RETINA; SURFACE CHARGE; SUSPENSION; SUSTAINED DRUG RELEASE; VITREOUS BODY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DEXAMETHASONE; DIFFUSION; EYE DISEASES; INTRAVITREAL INJECTIONS; LACTIC ACID; MATERIALS TESTING; METABOLIC CLEARANCE RATE; NANOCAPSULES; POLYETHYLENE GLYCOLS; POLYGLYCOLIC ACID; POSTERIOR EYE SEGMENT; RABBITS; TISSUE DISTRIBUTION; VITAMIN E;

EID: 84883359516     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2013.1646     Document Type: Article

References (28)

1. P. M. Hughes, O. Olejnik, J. E. Chang-Lin, C. G. Wilson, Topical and systemic drug delivery to the posterior segments. Adv. Drug Deliv. Rev. 57, 2010 (2005).
2. D. H. Geroski and H. F. Edelhauser, Drug delivery for posterior segment eye disease. Invest. Ophthalmol. Vis. Sci. 41, 961 (2000).
3. T. Y asukawa, Y. Ogura, E. Sakurai, Y. Tabata, and H. Kimura, Intraocular sustained drug delivery using implantable polymeric devices. Adv. Drug Deliv. Rev. 57, 2033 (2005).
4. C. Martínez-Sancho, R. Herrero-Vanrell, and S. Negro, Vitamin A palmitate and aciclovir biodegradable microspheres for intraocular sustained release. Int. J. Pharm. 326, 100 (2006).
5. A. A. Moshfeghi and G. A. Peyman, Micro- and nanoparticulates. Adv. Drug Deliv. Rev. 57, 2047 (2005).
6. J. Kathawate and S. Acharya, Computational modeling of intravitreal drug delivery in the vitreous chamber with different vitreous substitutes. Int. J. Heat Mass. Transfer. 51, 5598 (2008).
7. R. R. Caspi, C. C. Chan, W. C. Leake, M. Hiquchi, B. Wiqqert, and G. J. Chader, Experimental autoimmune uveoretinitis in mice. Induction by a single eliciting event and dependence on quantitative parameters of immunization. J. Autoimmun. 3, 237 (1990).
8. C. C. Chan, R. R. Caspi, M. Ni, W. C. Leake, B. Wiggert, G. J. Chader, and B. B. Nussenblatt, Pathology of experimental autoimmune uveoretinitis in mice. J. Autoimmun. 3, 247 (1990).
9. Y. De-Kozak, M. Mirshahi, C. Boucheix, and J. P. Faure, Prevention of experimental autoimmune uveoretinitis by active immunization with autoantigenspecific monoclonal antibodies. Eur. J. Immunol. 17, 541 (1987).
10. J. J. Schalken, H. J. Winkens, A. H. van Vugt, P. H. Bovée-Geurts, W. J. de Grip, and R. M. Broekhuyse, Rhodopsin-induced experimental autoimmune uveoretinitis: Dose-dependent clinicopathological features. Exp. Eye Res. 47, 135 (1988).
11. M. Merodio, J. M. Irache, F. Valamanesh, and M. Mirshahi, Ocular disposition and tolerance of ganciclovir-loaded albumin nanoparticles after intravitreal injection in rats. Biomaterials 23, 1587 (2002).
12. S. K. Sahoo, F. Dilnawaz, and S. Krishnakumar, Nanotechnology in ocular drug delivery. Drug Discov. Today. 13, 144 (2008).
13. L. Q. Huang, H. B. Chen, Y. Zheng, X. S. Song, R. Y. Liu, K. X. Liu, X. W. Zeng, and L. Mei, Nanoformulation of d-α-tocopheryl polyethylene glycol 1000 succinate-b-poly(ε-caprolactone-ran-glycolide) diblock copolymer for breast cancer therapy. Integrative Biology. 3, 951 (2011).
14. O. Aydemir, S. Celebi, T. Yilmaz, H. Yekeler, and A. S. Kükner, Protective effects of vitamin E forms (alpha-tocopherol, gammatocopherol and d-alpha-tocopherol polyethylene glycol 1000 succinate) on retinal edema during ischemia-reperfusion injury in the guinea pig retina. Int. Ophthalmol. 25, 283 (2004).
15. S. Muñoz-Fernández and E. Martín-Mola, Uveitis. Best Pract. Res. Clin. Rheumatol. 20, 487 (2006).
16. C. Gómez-Gaete, E. Fattal, L. Silva L, M. Besnard, and N. Tsapis, Dexamethasone acetate encapsulation into Trojan particles. J. Control Release 128, 41 (2008).
17. R. S. Hunter and A. Lobo, Dexamethasone intravitreal implant for the treatment of noninfectious uveitis. Clin Ophthalmol. 5, 1613 (2011).
18. L. Mei, Y. Zhang, Y. Zheng, G. Tian, C. Song, D. Yang, H. Chen, H. Sun, Y. Tian, K. Liu, Z. Li, and L. Huang, A novel docetaxelloaded poly (ε-caprolactone)/pluronic F68 nanoparticle overcoming multidrug resistance for breast cancer treatment. Nanoscale Res. Lett. 4, 1530 (2009)
19. Y. Ma, Y. Zheng, K. Liu, G. Tian, Y. Tian, L. Xu, F. Yan, L. Huang, and L. Mei, Nanoparticles of poly(lactide-co-glycolide)-da- tocopheryl polyethylene glycol 1000 succinate random copolymer for cancer treatment. Nanoscale Res. Lett. 5, 1161 (2010).
20. Z. Zhang, L. Mei, and S. S. Feng, Vitamin E D-α- tocopheryl polyethylene glycol 1000 succinate-based nanomedicine. Nanomedicine 7, 1645 (2012).
21. K. Hosseini, D. Matsushima, Johnson J, G. Widera, K. Nyam, L. Kim, Y. Xu, Y. Yao, and M. Cormier, Pharmacokinetic study of dexamethasone disodium phosphate using intravitreal, subconjunctival, and intravenous delivery routes in rabbits. J. Ocul. Pharmacol. Ther. 24, 301 (2008).
22. S. S. Feng, L. Mei, P. Anitha, C. W. Gan, and W. Zhou, Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of docetaxel. Biomaterials 30, 3297 (2009).
23. L. Mei, H. Sun, and C. Song, Local delivery of modified paclitaxelloaded PCL/F68 nanoparticles for long-term inhibition of hyperplasia in a rabbit arterial balloon injury model. J. Pharm. Sci. 98, 2040 (2009).
24. L. Mei, H. Sun, X. Jin, D. Zhu, R. Sun, M. Zhang, and C. Song, Modified paclitaxel-loaded nanoparticles for inhibition of hyperplasia in a rabbit arterial balloon injury model. Pharm. Res. 24, 955 (2007).
25. Y. Zhang, L. Tang, L. Sun, J. Bao, C. Song, L. Huang, K. Liu, Y. Tian, G. Tian, Z. Li, H. Sun, and L. Mei, A novel paclitaxel-loaded Poly (ε-caprolactone)/Poloxamer 188 blend nanoparticle overcoming multidrug resistance for cancer treatment. Acta Biomater. 6, 2045 (2010).
26. F. Yan, C. Zhang, Y. Zheng, L. Mei, L. Tang, C. Song, H. Sun, and L. Huang, The effect of poloxamer 188 on nanoparticle morphology, size, cancer cell uptake, and cytotoxicity. Nanomedicine 6, 170 (2010).
27. K. Okabe, H. Kimura, J. Okabe, A. Kato, N. Kunou, and Y. Ogura, Intraocular tissue distribution of betamethasone after intrascleral administration using a nonbiodegradable sustained drug delivery device. Invest. Ophthalmol. Vis. Sci. 44, 2702 (2003).
28. J. M. Molleda, R. H. Tardón, J. M. Gallardo, and E. M. Martín- Suárez, The ocular effects of intravitreal triamcinolone acetonide in dogs. Vet. J. 176, 326 (2008).